Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?

Published:2016-10-18 Issue:2 Volume:24 Page:237-244
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Bonenfant J.¹,Bajeux E.²,Deburghgraeve V.¹³⁴,Le Page E.¹³⁴,Edan G.¹³⁴,Kerbrat A.¹⁴

Affiliation:

1. Department of Neurology; University Hospital; Rennes France

2. Department of Epidemiology and Public Health; University Hospital; Rennes France

3. CIC-P 1414 Inserm; University Hospital; Rennes France

4. West Neuroscience Network of Excellence (WENNE); Rennes France

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ene.13181/fullpdf

Reference22 articles.

1. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis;Filippini;Cochrane Database Sys Rev,2013

2. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis;European Study Group on interferon beta-1b in secondary progressive MS;Lancet,1998

3. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results;Secondary Progressive Efficacy Clinical Trial of Recombinant;Neurology,2001

4. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS;Cohen;Neurology,2002

5. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study;Panitch;Neurology,2004

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MS treatment de-escalation: review and commentary;Journal of Neurology;2024-08-02

2. De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis;Current Neurology and Neuroscience Reports;2024-07-12

3. As time goes by: Treatment challenges in elderly people with multiple sclerosis;Journal of Neuroimmunology;2024-06

4. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS;JAMA Neurology;2024-05-01

5. Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review;Frontiers in Immunology;2024-04-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3